RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency: post-hoc analysis of the GeparOla trial.
Villacampa G, Llop-Guevara A, Filmann N, Herencia A, Fasching PA, Karn T, Marmé F, Klare P, Müller V, Stefek A, Schem C, Uleer C, Fehm T, Doering G, Stickeler E, van Mackelenbergh M, Felder B, Nekljudova V, Balmaña J, Denkert C, Loibl S, Serra V.
Villacampa G, et al. Among authors: muller v.
Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-3148. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 39786436